{"id":"fb102","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FB102 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"FB102 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:53:33.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07205159","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","status":"RECRUITING","sponsor":"Forte Biosciences, Inc.","startDate":"2025-10-23","conditions":"Alopecia Areata","enrollment":32},{"nctId":"NCT06905873","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo","status":"RECRUITING","sponsor":"Forte Biosciences, Inc.","startDate":"2025-03-25","conditions":"Vitiligo","enrollment":64},{"nctId":"NCT06982963","phase":"PHASE2","title":"Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease","status":"RECRUITING","sponsor":"Forte Biosciences, Inc.","startDate":"2025-08-04","conditions":"Celiac Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"FB102","genericName":"FB102","companyName":"Forte Biosciences, Inc.","companyId":"forte-biosciences-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"FB102 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}